arrow
D

Deniz Tural

university of health science
H指数:21
被引数:1,869

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma

avelumab维持治疗转移性尿路上皮癌的预后因素

2026-09-020
PRE
Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations

奥拉帕利在全球真实世界中对具有同源重组修复改变的转移性去势抵抗性前列腺癌患者的疗效

2026-08-310
OAAI
Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

Gustave Roussy免疫评分对接受一线免疫疗法为基础的联合治疗转移性肾细胞癌的预后影响:土耳其肿瘤学组肾癌联盟(TKCC)的研究结果

2026-08-060
OA
Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study

在EGFR突变NSCLC发生SCLC转化后,联合免疫疗法与化疗可能改善生存:一项多中心真实世界研究

2026-08-010
PRE
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study

转移时间作为转移性尿路上皮癌的预后因素:ARON-2研究的结果

2025-11-210
PRE
177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study

177Lu-PSMA 与 cabazitaxel 在去势抵抗性前列腺癌患者中的真实世界疗效与安全性数据:ARON-3 研究结果

2025-09-120
PREAI
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study
2025-02-200
OAAI
Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

舒尼替尼在转移性肾细胞癌中的应用:土耳其肿瘤学组肾癌协作组中不同风险组的临床结局

2025-02-101
OAAI
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project
2024-08-060
PRE
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project

Pembrolizumab在晚期上尿路尿路上皮癌患者中的应用: 来自ARON-2项目的真实世界研究

2024-06-083
PRE
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study
2023-11-023
PRE
The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors
2022-10-0311
OAAI
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

晚期ALK阳性非小细胞肺癌患者一线阿来替尼治疗疗效和安全性的真实数据: 土耳其肿瘤学组研究

2022-06-231
PRE
Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study
2022-06-011
OAAI
Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database
2021-11-024
PRE